Stem cell therapies are moving from laboratory promise to clinical reality, with patients walking after paralysis and damaged organs regenerating. Yet regulatory caution, manufacturing challenges, and inconsistent results mean the revolution will arrive gradually, transforming not just medicine but how humanity thinks about aging and human limitation.
Scientists are pioneering mitochondrial transplants that replace damaged cellular powerhouses with healthy ones, showing promise for treating Parkinson's, heart failure, stroke, and aging itself—with first clinical trials launching now.
Scientists discovered that extracellular vesicles (EVs)—nano-sized packages released by all cells—are both cancer's secret weapon for metastasis and stem cells' healing tool. Cancer hijacks EVs to prime distant organs, suppress immunity, and transfer drug resistance, while stem-cell EVs repair hearts, regenerate cartilage, and modulate inflammation without transplanting cells. Over 200 clinical trials are engineering EVs as programmable drug carriers and liquid biopsy biomarkers. Mastering th...
Loading featured articles...